NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Core Insights - NuCana plc announced promising data for its lead anti-cancer drugs NUC-7738 and NUC-3373, indicating potential for improved treatment outcomes for cancer patients [3] - The company is well-capitalized with cash reserves expected to last into 2029, following successful fundraising efforts [9][8] - Initial data from the expansion study of NUC-7738 is anticipated in Q4 2025, with final data expected in 2026 [1][6] Clinical Development Updates - NUC-7738 showed enhanced effectiveness when combined with PD-1 inhibitors, leading to increased tumor cell killing in a real-time organoid model [3] - The ongoing NuTide:701 study is recruiting additional patients with PD-1 inhibitor-resistant melanoma to explore optimal registration strategies [3] - NUC-3373 demonstrated durable activity in patients who had exhausted standard treatment options, with notable cases of significant tumor reduction [3] Financial Highlights - As of September 30, 2025, NuCana reported cash and cash equivalents of £25.2 million, a significant increase from £8.4 million in June 2025 [7] - The company reported a net loss of £0.3 million for Q3 2025, a decrease from a net loss of £4.5 million in Q3 2024 [10] - For the nine months ended September 30, 2025, the net loss was £26.9 million, compared to £18.3 million for the same period in 2024 [11] Anticipated Milestones - Initial data from the Phase 1/2 expansion study of NUC-7738 is expected in Q4 2025, with regulatory guidance from the FDA anticipated in 2026 [6] - Final data from the NuTide:701 study is also expected in 2026, alongside nonclinical data on NUC-3373's mode of action [6]